Nutreco, global leader in animal nutrition and aquafeed, today announces that it has taken a minority stake in animal health’s most advanced microbiome biotech company, BiomEdit. The two companies recently entered into a ground-breaking, long-term strategic research and commercial partnership – the first since BiomEdit was founded – to bring livestock and aquaculture producers innovative and truly novel feed additives developed through microbiome technology. Today’s announcement represents a further strengthening of this partnership.

“Through this investment, we are reinforcing the unique collaboration that brings together BiomEdit’s state-of-the-art microbiome discovery platform and Nutreco’s customer access and distribution capabilities,” said Fulco van Lede, CEO Nutreco. “We’re excited about its potential to help us super-charge our supply of proprietary ultra-specialty ingredients, speed up progress on our purpose of Feeding the Future and create a more sustainable future for our industry.”

“Nutreco’s investment in BiomEdit underscores our strategic partnership and a shared mission to create novel animal health solutions through the untapped potential of the microbiome,” said Aaron Schacht, CEO of BiomEdit. “We are pleased that Nutreco, a global leader in animal nutrition and aquafeed, is joining our roster of world-class Series A investors to help fuel innovation in feed additive products.”

Nutreco took the minority stake in BiomEdit through the company’s recent Series A financing round, initially raised in April 2022 in its carve-out from Elanco Animal Health (NYSE: ELAN) including contributions of assets and technology from Ginkgo Bioworks (NYSE: DNA) and Elanco. Anterra Capital, Viking Global Investors and Ferment are also investors in BiomEdit.